1. Home
  2. ACB vs MDWD Comparison

ACB vs MDWD Comparison

Compare ACB & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACB
  • MDWD
  • Stock Information
  • Founded
  • ACB 2013
  • MDWD 2000
  • Country
  • ACB Canada
  • MDWD Israel
  • Employees
  • ACB N/A
  • MDWD N/A
  • Industry
  • ACB Pharmaceuticals and Biotechnology
  • MDWD Medicinal Chemicals and Botanical Products
  • Sector
  • ACB Health Care
  • MDWD Health Care
  • Exchange
  • ACB Nasdaq
  • MDWD Nasdaq
  • Market Cap
  • ACB 256.5M
  • MDWD 208.2M
  • IPO Year
  • ACB N/A
  • MDWD 2014
  • Fundamental
  • Price
  • ACB $4.87
  • MDWD $16.67
  • Analyst Decision
  • ACB
  • MDWD Strong Buy
  • Analyst Count
  • ACB 0
  • MDWD 2
  • Target Price
  • ACB N/A
  • MDWD $35.00
  • AVG Volume (30 Days)
  • ACB 2.1M
  • MDWD 101.5K
  • Earning Date
  • ACB 11-05-2025
  • MDWD 08-14-2025
  • Dividend Yield
  • ACB N/A
  • MDWD N/A
  • EPS Growth
  • ACB N/A
  • MDWD N/A
  • EPS
  • ACB N/A
  • MDWD N/A
  • Revenue
  • ACB $262,403,032.00
  • MDWD $19,858,000.00
  • Revenue This Year
  • ACB $9.42
  • MDWD $20.37
  • Revenue Next Year
  • ACB $3.01
  • MDWD $25.91
  • P/E Ratio
  • ACB N/A
  • MDWD N/A
  • Revenue Growth
  • ACB 28.58
  • MDWD N/A
  • 52 Week Low
  • ACB $3.42
  • MDWD $14.14
  • 52 Week High
  • ACB $6.91
  • MDWD $22.51
  • Technical
  • Relative Strength Index (RSI)
  • ACB 46.88
  • MDWD 34.38
  • Support Level
  • ACB $4.75
  • MDWD $16.29
  • Resistance Level
  • ACB $4.95
  • MDWD $17.06
  • Average True Range (ATR)
  • ACB 0.25
  • MDWD 0.63
  • MACD
  • ACB -0.05
  • MDWD -0.01
  • Stochastic Oscillator
  • ACB 22.36
  • MDWD 18.63

About ACB Aurora Cannabis Inc.

Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: